Carmen Chung1, Gary Remington. 1. Centre for Addiction and Mental Health, Schizophrenia Program, 250 College Street, Toronto, Ontario, M5T 1R8, Canada.
Abstract
RATIONALE: With other atypical antipsychotics now available, having predictors of clozapine response would be of considerable value, offering clinicians guidance in their decision as to when, and if, a trial of clozapine is warranted. OBJECTIVES: The aim was to review existing evidence regarding identified predictors and markers of clozapine response. METHODS: Relevant studies were identified through PUBMED searches (1975-June 2004) and cross-referencing of reviews and included studies. The data were summarized under two main categories: clinical (general, neurological, cognitive/neuropsychological, clozapine levels) and biological (biochemical, endocrine, genetic, metabolic, morphological, dopamine D2 receptor occupancy). 'Reliable' predictors/markers were defined a priori as those with support of at least two independent reports that addressed overall response, with no contradictory findings to date. 'Potential' predictors/markers had the support of a single report that addressed overall response and at least one other evaluating treatment outcome but not directly addressing response status. RESULTS AND CONCLUSIONS: Higher baseline clinical symptoms and functioning in the previous years and low cerebrospinal homovanillic acid/5-hydroxyindoleacetic acid levels were identified as reliable. Three potential measures were identified: reduction of frontal cortex metabolic activity, reduction of caudate volume, and improvement in P50 sensory gating.
RATIONALE: With other atypical antipsychotics now available, having predictors of clozapine response would be of considerable value, offering clinicians guidance in their decision as to when, and if, a trial of clozapine is warranted. OBJECTIVES: The aim was to review existing evidence regarding identified predictors and markers of clozapine response. METHODS: Relevant studies were identified through PUBMED searches (1975-June 2004) and cross-referencing of reviews and included studies. The data were summarized under two main categories: clinical (general, neurological, cognitive/neuropsychological, clozapine levels) and biological (biochemical, endocrine, genetic, metabolic, morphological, dopamine D2 receptor occupancy). 'Reliable' predictors/markers were defined a priori as those with support of at least two independent reports that addressed overall response, with no contradictory findings to date. 'Potential' predictors/markers had the support of a single report that addressed overall response and at least one other evaluating treatment outcome but not directly addressing response status. RESULTS AND CONCLUSIONS: Higher baseline clinical symptoms and functioning in the previous years and low cerebrospinal homovanillic acid/5-hydroxyindoleacetic acid levels were identified as reliable. Three potential measures were identified: reduction of frontal cortex metabolic activity, reduction of caudate volume, and improvement in P50 sensory gating.
Authors: P Huezo-Diaz; M J Arranz; J Munro; S Osborne; A Makoff; R W Kerwin; J Austin; M O'Donovan Journal: Schizophr Res Date: 2004-02-01 Impact factor: 4.939
Authors: A K Malhotra; D Goldman; R W Buchanan; W Rooney; A Clifton; M H Kosmidis; A Breier; D Pickar Journal: Mol Psychiatry Date: 1998-01 Impact factor: 15.992
Authors: J A Frazier; J N Giedd; D Kaysen; K Albus; S Hamburger; J Alaghband-Rad; M C Lenane; K McKenna; A Breier; J L Rapoport Journal: Am J Psychiatry Date: 1996-04 Impact factor: 18.112
Authors: M H Kronig; R A Munne; S Szymanski; A Z Safferman; S Pollack; T Cooper; J M Kane; J A Lieberman Journal: Am J Psychiatry Date: 1995-02 Impact factor: 18.112
Authors: G M Simpson; R C Josiassen; J K Stanilla; J de Leon; C Nair; G Abraham; A Odom-White; R M Turner Journal: Am J Psychiatry Date: 1999-11 Impact factor: 18.112
Authors: Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero Journal: Schizophr Res Date: 2015-02-13 Impact factor: 4.939
Authors: Ruta Samanaite; Amy Gillespie; Kyra-Verena Sendt; Grant McQueen; James H MacCabe; Alice Egerton Journal: Front Psychiatry Date: 2018-07-26 Impact factor: 4.157
Authors: Amir Krivoy; Eromona Whiskey; Henrietta Webb-Wilson; Dan Joyce; Derek K Tracy; Fiona Gaughran; James H MacCabe; Sukhwinder S Shergill Journal: Ther Adv Psychopharmacol Date: 2021-10-16